| DOI | Resolve DOI: https://doi.org/10.1038/bjc.2011.427 |
|---|
| Author | Search for: Bertrand, Y.; Search for: Currie, J.-C.; Search for: Poirier, J.; Search for: Demeule, M.; Search for: Abulrob, A.1; Search for: Fatehi, D.1; Search for: Stanimirovic, D.1; Search for: Sartelet, H.; Search for: Castaigne, J.-P.; Search for: Béliveau, R. |
|---|
| Affiliation | - National Research Council of Canada. NRC Institute for Biological Sciences
|
|---|
| Format | Text, Article |
|---|
| Subject | brain cancer; cancer phenotype; Angiopep-2; blood–brain barrier; low-density lipoprotein receptor-related protein 1 (LRP1) |
|---|
| Abstract | ANG1005 consists of three molecules of paclitaxel conjugated via ester bonds to the 19-amino-acid peptide Angiopep-2. The new chemical agent has been shown to cross the blood–brain barrier (BBB) by receptor-mediated transcytosis via low-density lipoprotein receptor-related protein 1 (LRP1). The experiments here examined the role of LRP1 in the subsequent endocytosis of drug into cancer cells. |
|---|
| Publication date | 2011-11-22 |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| NPARC number | 19254218 |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | 1e9d211b-2982-49ac-864f-b435058f38b8 |
|---|
| Record created | 2012-03-08 |
|---|
| Record modified | 2020-04-21 |
|---|
